Innoviva earnings were $271.2M for the trailing 12 months ending Dec 31, 2025, with 986.5% growth year over year. The latest INVA earnings report on Dec 31, 2025 announced Q4 2025 earnings of $164.2M, up 82.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, INVA reported annual earnings of $271.2M, with 1,059.2% growth.
INVA past earnings growth
How has INVA's earnings growth performed historically?
On INVA's earnings call on Invalid Date, Innoviva (NASDAQ: INVA) reported Q4 2025 earnings per share (EPS) of $2.37, up 640.63% year over year. Total INVA earnings for the quarter were $164.15 million. In the same quarter last year, Innoviva's earnings per share (EPS) was $0.32.
As of the last Innoviva earnings report, Innoviva is currently profitable. Innoviva's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $271.17 million, a 1,059.22% increase year over year.
What was INVA's earnings growth in the past year?
As of Innoviva's earnings date in Invalid Date, Innoviva's earnings has grown 986.49% year over year. This is 905.26 percentage points higher than the US Biotechnology industry earnings growth rate of 81.22%. INVA earnings in the past year totalled $271.17 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.